8-K: Harvard Bioscience Secures Debt Waiver, Faces Refinancing Deadline

Harvard Bioscience, Inc. received a waiver for debt defaults and amended its credit agreement, but faces substantial doubt about its ability to continue as a going concern without new capital.

Summary

• Harvard Bioscience, Inc. (the Company) entered into a Sixth Amendment to its Credit Agreement on August 8, 2025.
• The amendment waives events of default related to the Company's failure to meet certain refinancing milestones and non-compliance with consolidated net leverage ratio and consolidated fixed charge coverage ratio covenants as of June 30, 2025.
• Lenders agreed not to test financial covenants for the fiscal quarters ended March 31, 2025, and September 30, 2025.
• The Company must maintain minimum liquidity of $3.0 million and provide certain financial reports.
• A mandatory prepayment event was added for cash proceeds from refinancing or sale of equity/assets.
• The applicable interest rate margin was increased to a rate per annum based on Secured Overnight Financing Rate (SOFR) plus 700 basis points.
• The Company must accomplish steps towards refinancing or repaying the Credit Agreement by December 5, 2025, with failure constituting an event of default.
• The Company agreed to pay fees of $0.4 million (1.00% of outstanding debt) to the Lenders, with 25% paid upfront and 75% due upon refinancing/repayment or event of default.

Sentiment

Score: 2

Explanation: The filing indicates severe financial distress, including multiple covenant breaches, an explicit 'going concern' warning, increased borrowing costs, and uncertainty regarding future financing. While a waiver was granted, it comes with strict conditions and a tight deadline, highlighting the precarious financial position.

Positives

• Lenders waived existing events of default, providing immediate relief from covenant breaches.
• Financial covenants will not be tested for the fiscal quarters ended March 31, 2025, and September 30, 2025, offering a temporary reprieve.
• The waiver of 10% of the second installment of the amendment fee if no further event of default occurs and termination happens by December 5, 2025, provides a small incentive for timely resolution.

Negatives

• The Company failed to achieve refinancing milestones and comply with key financial covenants (net leverage ratio and fixed charge coverage ratio) as of June 30, 2025.
• The applicable interest rate margin was increased, leading to higher borrowing costs.
• A strict deadline of December 5, 2025, has been imposed for refinancing or repayment steps, with failure resulting in another event of default.
• The Company incurred $0.4 million in fees for the amendment.
• The Company explicitly stated "substantial doubt about the Company's ability to continue as a going concern."
• Ability to access alternative capital sources for refinancing is uncertain, with no assurance of availability or commercially acceptable terms.

Risks

• Substantial doubt about the Company's ability to continue as a going concern.
• Uncertainty regarding the Company's ability to access alternative sources of capital for refinancing.
• Risk that new capital may not be available, obtainable on commercially acceptable terms, or sufficient to meet objectives.
• Inability to pay debt obligations and fund operations beyond the repayment date if new capital is not secured or the Credit Agreement is not extended.
• Failure to accomplish refinancing or repayment steps by December 5, 2025, will constitute an event of default.
• Increased interest rate margin leads to higher debt servicing costs.

Future Outlook

The Company continues to explore alternative sources of capital to refinance its outstanding indebtedness, but its ability to access such capital is uncertain. There is no assurance that capital will be available, obtainable on commercially acceptable terms, or sufficient to meet objectives. Based on anticipated cash flows, the Company will be unable to pay debt obligations and fund operations beyond the repayment date unless new capital is secured or the Credit Agreement is extended.

Management Comments

• "The Company continues to explore alternative sources of capital that would allow it to refinance the outstanding indebtedness due under the Credit Agreement, but its ability to access such other sources of capital is uncertain."
• "There is no assurance that such capital will be available, be obtainable on commercially acceptable terms, or provide the Company with sufficient funds to meet its objectives."
• "Based on its anticipated cash flows from operations, unless the Company is able to access other sources of capital or extend the date for repayment under the Credit Agreement, the Company will be unable to pay its debt obligations and fund its operations beyond that date."
• "As a result, there is substantial doubt about the Company's ability to continue as a going concern."

Industry Context

This filing indicates a company facing significant financial distress, which is not uncommon for smaller companies in capital-intensive sectors or those experiencing operational challenges. The need for waivers and the "going concern" warning suggest a struggle to maintain liquidity and meet debt obligations, potentially due to market conditions, internal operational issues, or a combination. Such situations often lead to increased scrutiny from investors and potential difficulties in securing future financing on favorable terms, contrasting with more stable companies that can access capital markets easily.

Comparison to Industry Standards

• The explicit "going concern" warning is a severe indicator of financial distress, typically reserved for companies facing imminent liquidity crises, unlike financially robust peers in the life sciences tools sector.
• The need for a waiver of financial covenants and refinancing milestones suggests performance significantly below industry averages for debt service capacity and financial health.
• The increased interest rate margin (SOFR + 700 bps) is substantially higher than typical borrowing costs for healthy companies, reflecting the elevated risk perceived by lenders. For comparison, well-capitalized companies often secure loans at SOFR plus 100-300 bps, indicating Harvard Bioscience's borrowing costs are several times higher due to its distressed state.
• The imposition of a strict refinancing deadline (December 5, 2025) and the associated fees are common for companies in default, but are not standard practice for companies meeting their financial obligations.

Stakeholder Impact

• Shareholders: Significant negative impact due to "going concern" doubt, increased financial risk, potential dilution if new equity is raised, and uncertainty about future operations.
• Creditors (Lenders): Increased interest income due to higher margin, but also increased risk exposure due to the Company's financial distress and the need for waivers. They have secured a mandatory prepayment clause upon refinancing or asset sale.
• Employees: Potential uncertainty regarding job security and the Company's long-term viability due to the "going concern" warning.
• Customers/Suppliers: Potential concerns about the Company's stability and ability to fulfill long-term commitments or pay for supplies, which could affect business relationships.

Next Steps

• Maintain minimum liquidity of $3.0 million.
• Provide administrative agent with certain financial reports.
• Accomplish steps towards refinancing or repayment of the Credit Agreement by December 5, 2025.
• Continue exploring alternative sources of capital for refinancing.

Key Dates

Recommendation

The filing reveals severe financial distress, including multiple covenant defaults, an explicit "substantial doubt about the Company's ability to continue as a going concern" warning, and significantly increased borrowing costs. While a temporary waiver was secured, it comes with a tight deadline for refinancing and no assurance of obtaining necessary capital on acceptable terms. This indicates a high risk of bankruptcy or significant dilution, making the stock a strong sell for investors.

Keywords

Harvard Bioscience, HBIO, SEC Filing, 8-K, Credit Agreement, Debt Default, Waiver, Refinancing, Going Concern, Financial Covenants, Liquidity, Corporate Finance, Biotechnology, Life Sciences Tools